See more : Argo Investments Limited (ARG.AX) Income Statement Analysis – Financial Results
Complete financial analysis of MDxHealth SA (0O8G.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MDxHealth SA, a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Shandong Wohua Pharmaceutical Co., Ltd. (002107.SZ) Income Statement Analysis – Financial Results
- Shenzhen Etmade Automatic Equipment Co., Ltd. (300812.SZ) Income Statement Analysis – Financial Results
- Eisai Co., Ltd. (ESALF) Income Statement Analysis – Financial Results
- Zuger Kantonalbank (ZUGER.SW) Income Statement Analysis – Financial Results
- Hikari Business Form Co., Ltd. (3948.T) Income Statement Analysis – Financial Results
MDxHealth SA (0O8G.L)
About MDxHealth SA
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 70.19M | 37.05M | 22.24M | 18.46M | 11.79M | 24.79M | 33.76M | 28.47M | 16.24M | 9.64M | 5.49M | 4.48M |
| Cost of Revenue | 26.26M | 17.84M | 11.68M | 10.42M | 11.76M | 10.17M | 8.50M | 9.60M | 6.36M | 5.33M | 4.21M | 880.56K |
| Gross Profit | 43.93M | 19.22M | 10.56M | 8.04M | 30.00K | 14.62M | 25.26M | 18.88M | 9.88M | 4.31M | 1.28M | 3.60M |
| Gross Profit Ratio | 62.58% | 51.87% | 47.50% | 43.58% | 0.25% | 58.97% | 74.81% | 66.29% | 60.86% | 44.71% | 23.31% | 80.37% |
| Research & Development | 6.38M | 5.50M | 5.59M | 4.54M | 9.00M | 3.74M | 2.92M | 1.88M | 3.06M | 1.96M | 3.32M | 5.15M |
| General & Administrative | 23.01M | 23.30M | 13.92M | 13.99M | 15.20M | 13.27M | 29.63M | 27.39M | 18.85M | 13.98M | 8.58M | 0.00 |
| Selling & Marketing | 36.92M | 25.70M | 17.45M | 16.75M | 17.81M | 25.83M | 2.99M | 2.02M | 1.74M | 1.15M | 1.02M | 0.00 |
| SG&A | 59.93M | 49.01M | 31.37M | 30.74M | 33.01M | 39.10M | 32.62M | 29.41M | 20.59M | 15.14M | 9.60M | 7.27M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 82.53M | 60.75M | 37.70M | 35.36M | 43.40M | 42.92M | 35.60M | 31.41M | 23.13M | 16.91M | 13.02M | 12.39M |
| Cost & Expenses | 108.80M | 78.59M | 49.38M | 45.78M | 55.15M | 53.10M | 44.10M | 41.01M | 29.49M | 22.24M | 17.23M | 13.27M |
| Interest Income | 6.67M | 2.35M | 1.64M | 1.10M | 274.58K | 53.25K | 0.00 | 89.31K | 79.18K | 7.44K | 2.90K | 37.16K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 6.52M | 2.71M | 1.06M | 2.10M | 892.39K | 1.12M | 808.50K | 759.13K | 552.45K | 272.63K | 303.53K | 389.09K |
| EBITDA | -21.59M | -35.58M | -24.85M | -24.29M | -35.88M | -26.90M | -9.42M | -11.45M | -12.69M | -12.40M | -11.32M | -8.31M |
| EBITDA Ratio | -30.76% | -96.03% | -111.72% | -131.58% | -304.42% | -108.53% | -27.91% | -40.20% | -78.13% | -128.64% | -206.42% | -185.22% |
| Operating Income | -26.74M | -38.48M | -27.88M | -26.85M | -36.88M | -28.02M | -10.23M | -12.20M | -13.24M | -12.68M | -11.63M | -8.70M |
| Operating Income Ratio | -38.09% | -103.86% | -125.37% | -145.45% | -312.91% | -113.03% | -30.30% | -42.86% | -81.53% | -131.46% | -211.95% | -193.89% |
| Total Other Income/Expenses | -16.36M | -5.56M | -1.12M | -1.81M | -6.80M | 3.74M | -105.85K | 222.02K | 1.06M | 71.88K | -119.09K | -51.57K |
| Income Before Tax | -43.10M | -44.04M | -29.00M | -28.66M | -43.68M | -28.36M | -10.34M | -12.62M | -13.33M | -12.60M | -11.75M | -8.75M |
| Income Before Tax Ratio | -61.40% | -118.86% | -130.41% | -155.27% | -370.60% | -114.42% | -30.61% | -44.33% | -82.05% | -130.72% | -214.12% | -195.04% |
| Income Tax Expense | 1.00K | 0.00 | 0.00 | 0.00 | 575.00K | 35.79K | 94.19K | 107.36K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -43.10M | -44.04M | -29.00M | -28.66M | -43.10M | -28.33M | -10.24M | -12.52M | -13.33M | -12.60M | -11.75M | -8.75M |
| Net Income Ratio | -61.40% | -118.86% | -130.41% | -155.27% | -365.72% | -114.27% | -30.33% | -43.96% | -82.05% | -130.72% | -214.12% | -195.04% |
| EPS | -1.66 | -2.78 | -2.38 | -3.44 | -6.89 | -4.92 | -2.08 | -2.76 | -3.23 | -3.63 | -3.91 | -3.96 |
| EPS Diluted | -1.66 | -2.78 | -2.38 | -3.44 | -6.89 | -4.92 | -2.05 | -2.72 | -3.23 | -3.63 | -3.91 | -3.96 |
| Weighted Avg Shares Out | 25.91M | 15.87M | 12.19M | 8.32M | 6.26M | 5.76M | 4.92M | 4.54M | 4.13M | 3.48M | 3.00M | 2.21M |
| Weighted Avg Shares Out (Dil) | 25.91M | 15.87M | 12.19M | 8.32M | 6.26M | 5.76M | 4.99M | 4.61M | 4.13M | 3.48M | 3.00M | 2.21M |
Source: https://incomestatements.info
Category: Stock Reports